Welcome to our dedicated page for Ludwig Enter SEC filings (Ticker: LUDG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage diagnostics companies like Ludwig Enterprises bury pivotal details—R&D budgets, patent milestones, dilution risks—inside dense SEC filings. If you have ever opened Ludwig’s 300-page annual report and wondered where the mRNA genomics spend is hiding, you know the problem.
Stock Titan solves it. Our AI-powered summaries translate every Ludwig Enterprises annual report 10-K simplified, each Ludwig Enterprises quarterly earnings report 10-Q filing, and all Ludwig Enterprises 8-K material events explained into clear insights you can scan in minutes. Want to track lab-coat insiders? Receive instant alerts on Ludwig Enterprises Form 4 insider transactions real-time—including option grants to leading researchers and any executive stock sales.
Here’s what you’ll uncover, updated the second documents hit EDGAR:
- Cash-burn trends and clinical trial spending without wading through accounting footnotes.
- Patent additions or licensing deals flagged inside 8-Ks, paired with AI context on competitive impact.
- Compensation tables from the Ludwig Enterprises proxy statement executive compensation summarized for quick comparison.
- Side-by-side Ludwig Enterprises earnings report filing analysis to spot revenue inflection points once Revealia™ commercializes.
- Every Ludwig Enterprises insider trading Form 4 transactions trend charted to reveal conviction from scientists and directors.
Whether you search for “understanding Ludwig Enterprises SEC documents with AI” or need granular data before your next biotech thesis, Stock Titan’s real-time feed and expert analysis keep you ahead of the curve—with no medical dictionary required.
Ludwig Enterprises (LUDG) reported Q3 2025 results. The company posted net income of $31,252 for the quarter, driven largely by a $630,586 gain from the change in fair value of a derivative liability, while operations remained unprofitable. For the nine months, it recorded a net loss of $1,159,135 on $0 revenue as it continues developing mRNA-based diagnostics.
Liquidity is tight. Cash was $3,317 at September 30, 2025, with a working capital deficit of $3,319,663, notes payable of $1,270,009 and convertible notes payable of $687,593. Total liabilities were $3,572,502 and stockholders’ deficit was $(3,310,908). Management disclosed substantial doubt about the company’s ability to continue as a going concern.
Operating expenses reached $1,481,907 year-to-date, reflecting increased consulting, professional fees, and R&D. Financing provided $637,150 net cash year-to-date. The derivative liability stood at $267,473 at quarter-end. Shares outstanding were 162,569,807 as of November 5, 2025. Management said potential product sales could begin in Q4 2025, assuming approximately $10,000,000 of funding, with no assurance.
Ludwig Enterprises, Inc. (OTC: LUDG) filed Amendment No. 1 to its Form S-1 for a firm commitment public offering of common stock. The transaction is a primary issuance, with proceeds to the company, and is planned to begin as soon as practicable after the registration statement is declared effective. The offering is contingent on approval to list the common stock on a national exchange and on completing a reverse stock split “within a range from one-for-fifty to one-for-two-hundred-fifty.” If listing approval is not obtained, the company will terminate the offering.
The company plans to use proceeds for equipment, marketing, staffing, legal and accounting, company awareness, research and clinical trials, debt repayment, and to exercise an option to buy back certain shares. Prior to the offering, 162,569,807 shares of common stock were outstanding (without giving effect to the reverse split). The company states that, upon the effectiveness of the offering and its amended and restated articles, all outstanding Convertible Preferred Stock will automatically convert into common stock, and a portion of its convertible notes will convert into common stock.
Ludwig is an early-stage genomics diagnostics company focused on mRNA-based tests and qualifies as both an emerging growth company and a smaller reporting company. Recent financials show minimal revenue and net losses, and the auditors noted substantial doubt about the company’s ability to continue as a going concern.
FAQ
What is the current stock price of Ludwig Enter (LUDG)?
What is the market cap of Ludwig Enter (LUDG)?
